News and Updates

Explore Medicines360’s latest news and resources

Press Releases

FDA Approves Medicines360’s sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years

DUBLIN and SAN FRANCISCO – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg for […]

Read More >
Press Releases

Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs) SAN FRANCISCO and CHARLESTON, S.C. – Medicines360 and Afaxys Pharma, LLC, two mission-driven, socially conscious women’s health pharmaceutical companies, today announced their collaboration to promote Medicines360’s intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, which is […]

Read More >
Press Releases

Medicines360 and Direct Relief Partner to Expand Access for U.S. Women

Partnership will provide free hormonal IUDs to underserved women across the country SAN FRANCISCO and SANTA BARBARA, Calif. – Medicines360, a mission-driven women’s health pharmaceutical nonprofit and Direct Relief, a humanitarian aid organization, today announced their partnership to provide Medicines360’s hormonal IUD, LILETTA®, free of charge to clinics that serve the most vulnerable women in the United States, […]

Read More >
News

Medicines360 Expands Access To Contraception In Africa

Medicines360, the non-profit pharmaceutical company behind the hormonal IUD Liletta, is on a mission to increase women’s access to reproductive care around the world. This month, the female-led company announced the launch of Avibela, a hormonal IUD, in Madagascar.

Read More >
Press Releases

Medicines360, WCG, and Population Services International Announce Launch of AVIBELA™ Hormonal Intrauterine System in Madagascar

Approval Expands Contraceptive Access for Women in Madagascar SAN FRANCISCO and SAN DIEGO and WASHINGTON – Medicines360, WCG, and Population Services International (PSI) today announced the launch of AVIBELA (levonorgestrel-releasing intrauterine system) 52 mg in Madagascar. This is the first registration and launch of Medicines360’s hormonal intrauterine system (IUS or IUD) in Africa. AVIBELA’s introduction in Madagascar is supported by WCG’s Expanding Effective Contraceptive […]

Read More >
Press Releases

Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study

Medicines360 and Allergan Present Five-Year Multi-Center Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at 2018 ACOG Meeting SAN FRANCISCO and DUBLIN – Medicines360, a nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, presented five-year data from their ongoing multi-center U.S.-based […]

Read More >

FEATURED UPDATES

Press Releases

Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs) SAN FRANCISCO and CHARLESTON, S.C. – Medicines360 and Afaxys Pharma, LLC, two mission-driven, socially conscious women’s health pharmaceutical companies, today announced their collaboration to promote Medicines360’s intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, which is […]

Read More >
News

Medicines360 Expands Access To Contraception In Africa

Medicines360, the non-profit pharmaceutical company behind the hormonal IUD Liletta, is on a mission to increase women’s access to reproductive care around the world. This month, the female-led company announced the launch of Avibela, a hormonal IUD, in Madagascar.

Read More >
Press Releases

Medicines360 and Direct Relief Partner to Expand Access for U.S. Women

Partnership will provide free hormonal IUDs to underserved women across the country SAN FRANCISCO and SANTA BARBARA, Calif. – Medicines360, a mission-driven women’s health pharmaceutical nonprofit and Direct Relief, a humanitarian aid organization, today announced their partnership to provide Medicines360’s hormonal IUD, LILETTA®, free of charge to clinics that serve the most vulnerable women in the United States, […]

Read More >